Categories: BrainNewsPatient Care

Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, March 21, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.


A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call.

About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand.

The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.

Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

Contacts

Investor Contact
Marissa Bych

Gilmartin Group LLC

marissa@gilmartinir.com

Staff

Recent Posts

TERRY COLE FIX IT! DEA Blocks FDA Cannabis Trials While Contaminated Marijuana Floods State Markets

Terrance Cole's Choice: Reformer or Cover-Up Artist? New DEA Administrator Terrance Cole stands at a…

17 hours ago

Unlock the Power of MK-677: Your Guide to Buying MK-677 Ibutamoren Online

Buy MK-677 Ibutamoren capsules online to boost growth hormone and IGF-1 levels. Discover the benefits…

23 hours ago

Top 6 Best Joint Supplements for Dogs to Support Canine Joint Health and Pain Relief

Discover the best joint supplement for dogs designed to promote joint health, reduce arthritis symptoms,…

1 day ago

Buy MK-677 ibutamoren Capsules – Increase GH levels with Capsules

Buy MK-677 Ibutamoren capsules online to boost growth hormone and IGF-1 levels. Discover the benefits…

1 day ago